Vanguard Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Vanguard Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$127M	Buy	+5,122,666	New	+$122M	﹤0.01%	1341

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Capital Management's CPRX Position: Q1 2026 in Review

Vanguard Capital Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 5,122,666 shares worth $127M. The stake represents ﹤0.01% of the portfolio and ranks #1341 among its holdings.

380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Vanguard Capital Management held 5,122,666 shares of Catalyst Pharmaceutical worth $127M as of Q1 2026.
Catalyst Pharmaceutical was a new Vanguard Capital Management position in Q1 2026.
Catalyst Pharmaceutical made up ﹤0.01% of Vanguard Capital Management's portfolio in Q1 2026, its #1341 holding.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Vanguard Capital Management's 13F filing for Q1 2026, filed 8 May 2026.